Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer

B. Burford, A. Gentry-Maharaj, R. Graham, D. Allen, J. W. Pedersen, A. S. Nudelman, O. Blixt, E. O. Fourkala, D. Bueti, A. Dawnay, J. Ford, R. Desai, L. David, P. Trinder, B. Acres, T. Schwientek, A. Gammerman, C. A. Reis, L. Silva, H. OsórioR. Hallett, H. H. Wandall, U. Mandel, Michael A Hollingsworth, I. Jacobs, I. Fentiman, H. Clausen, J. Taylor-Papadimitriou, U. Menon, J. M. Burchell

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.

Original languageEnglish (US)
Pages (from-to)2045-2055
Number of pages11
JournalBritish journal of cancer
Volume108
Issue number10
DOIs
StatePublished - May 1 2013

Fingerprint

Glycopeptides
Pancreatic Neoplasms
Early Detection of Cancer
Autoantibodies
Ovarian Neoplasms
Lung Neoplasms
Breast Neoplasms
Guernsey
Serum
Neoplasms
Tandem Repeat Sequences
Biomarkers
Peptides
Research
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Burford, B., Gentry-Maharaj, A., Graham, R., Allen, D., Pedersen, J. W., Nudelman, A. S., ... Burchell, J. M. (2013). Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. British journal of cancer, 108(10), 2045-2055. https://doi.org/10.1038/bjc.2013.214

Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. / Burford, B.; Gentry-Maharaj, A.; Graham, R.; Allen, D.; Pedersen, J. W.; Nudelman, A. S.; Blixt, O.; Fourkala, E. O.; Bueti, D.; Dawnay, A.; Ford, J.; Desai, R.; David, L.; Trinder, P.; Acres, B.; Schwientek, T.; Gammerman, A.; Reis, C. A.; Silva, L.; Osório, H.; Hallett, R.; Wandall, H. H.; Mandel, U.; Hollingsworth, Michael A; Jacobs, I.; Fentiman, I.; Clausen, H.; Taylor-Papadimitriou, J.; Menon, U.; Burchell, J. M.

In: British journal of cancer, Vol. 108, No. 10, 01.05.2013, p. 2045-2055.

Research output: Contribution to journalArticle

Burford, B, Gentry-Maharaj, A, Graham, R, Allen, D, Pedersen, JW, Nudelman, AS, Blixt, O, Fourkala, EO, Bueti, D, Dawnay, A, Ford, J, Desai, R, David, L, Trinder, P, Acres, B, Schwientek, T, Gammerman, A, Reis, CA, Silva, L, Osório, H, Hallett, R, Wandall, HH, Mandel, U, Hollingsworth, MA, Jacobs, I, Fentiman, I, Clausen, H, Taylor-Papadimitriou, J, Menon, U & Burchell, JM 2013, 'Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer', British journal of cancer, vol. 108, no. 10, pp. 2045-2055. https://doi.org/10.1038/bjc.2013.214
Burford, B. ; Gentry-Maharaj, A. ; Graham, R. ; Allen, D. ; Pedersen, J. W. ; Nudelman, A. S. ; Blixt, O. ; Fourkala, E. O. ; Bueti, D. ; Dawnay, A. ; Ford, J. ; Desai, R. ; David, L. ; Trinder, P. ; Acres, B. ; Schwientek, T. ; Gammerman, A. ; Reis, C. A. ; Silva, L. ; Osório, H. ; Hallett, R. ; Wandall, H. H. ; Mandel, U. ; Hollingsworth, Michael A ; Jacobs, I. ; Fentiman, I. ; Clausen, H. ; Taylor-Papadimitriou, J. ; Menon, U. ; Burchell, J. M. / Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. In: British journal of cancer. 2013 ; Vol. 108, No. 10. pp. 2045-2055.
@article{af12de83c70a4c3c81a35fb77bdc7ddd,
title = "Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer",
abstract = "Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.",
author = "B. Burford and A. Gentry-Maharaj and R. Graham and D. Allen and Pedersen, {J. W.} and Nudelman, {A. S.} and O. Blixt and Fourkala, {E. O.} and D. Bueti and A. Dawnay and J. Ford and R. Desai and L. David and P. Trinder and B. Acres and T. Schwientek and A. Gammerman and Reis, {C. A.} and L. Silva and H. Os{\'o}rio and R. Hallett and Wandall, {H. H.} and U. Mandel and Hollingsworth, {Michael A} and I. Jacobs and I. Fentiman and H. Clausen and J. Taylor-Papadimitriou and U. Menon and Burchell, {J. M.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1038/bjc.2013.214",
language = "English (US)",
volume = "108",
pages = "2045--2055",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer

AU - Burford, B.

AU - Gentry-Maharaj, A.

AU - Graham, R.

AU - Allen, D.

AU - Pedersen, J. W.

AU - Nudelman, A. S.

AU - Blixt, O.

AU - Fourkala, E. O.

AU - Bueti, D.

AU - Dawnay, A.

AU - Ford, J.

AU - Desai, R.

AU - David, L.

AU - Trinder, P.

AU - Acres, B.

AU - Schwientek, T.

AU - Gammerman, A.

AU - Reis, C. A.

AU - Silva, L.

AU - Osório, H.

AU - Hallett, R.

AU - Wandall, H. H.

AU - Mandel, U.

AU - Hollingsworth, Michael A

AU - Jacobs, I.

AU - Fentiman, I.

AU - Clausen, H.

AU - Taylor-Papadimitriou, J.

AU - Menon, U.

AU - Burchell, J. M.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.

AB - Background:Autoantibodies have been detected in sera before diagnosis of cancer leading to interest in their potential as screening/early detection biomarkers. As we have found autoantibodies to MUC1 glycopeptides to be elevated in early-stage breast cancer patients, in this study we analysed these autoantibodies in large population cohorts of sera taken before cancer diagnosis.Methods:Serum samples from women who subsequently developed breast cancer, and aged-matched controls, were identified from UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and Guernsey serum banks to formed discovery and validation sets. These were screened on a microarray platform of 60mer MUC1 glycopeptides and recombinant MUC1 containing 16 tandem repeats. Additional case-control sets comprised of women who subsequently developed ovarian, pancreatic and lung cancer were also screened on the arrays.Results:In the discovery (273 cases, 273 controls) and the two validation sets (UKCTOCS 426 cases, 426 controls; Guernsey 303 cases and 606 controls), no differences were found in autoantibody reactivity to MUC1 tandem repeat peptide or glycoforms between cases and controls. Furthermore, no differences were observed between ovarian, pancreatic and lung cancer cases and controls.Conclusion:This robust, validated study shows autoantibodies to MUC1 peptide or glycopeptides cannot be used for breast, ovarian, lung or pancreatic cancer screening. This has significant implications for research on the use of MUC1 in cancer detection.

UR - http://www.scopus.com/inward/record.url?scp=84878554709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878554709&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.214

DO - 10.1038/bjc.2013.214

M3 - Article

C2 - 23652307

AN - SCOPUS:84878554709

VL - 108

SP - 2045

EP - 2055

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -